A Prescription for Blockchain in Health Care
Commercial applications are poised to go mainstream. Pharma and medtech companies, payers, and providers need to engage with the technology now.
The biotech and pharma industries continue their fast-paced digital evolution, while geopolitical and economic forces present hurdles that require more responsibility throughout the supply chain. Explore BCG’s latest thought leadership on biopharmaceuticals for key insights into the future of the life sciences industry.
Commercial applications are poised to go mainstream. Pharma and medtech companies, payers, and providers need to engage with the technology now.
Companies are using digital technologies to unlock new sources of economic value. But it takes more than technology. Leadership and culture both play important roles.
We haven’t seen an opportunity of this magnitude in the pharma industry for a very long time.
AI is gaining steam in business. Its rapid rise in China, in particular, has been a wake-up call for nations, industries, and executives globally.
“Double down on your loyalists”—and other insights to improve sales team efficiency.
A new approach reveals that scale is the most important cost factor in biopharma, but one kind of scale stands out for its contribution to cost reduction.
Supply chain managers need to ask certain key questions about how the new law will affect their companies’ global networks, investments, and M&A strategies—giving them a better understanding of how to make winning moves.
Companies are eager to shift more of the production they outsource to trusted strategic partners, but doing that right takes analysis and planning.
Changes to current US tax policy may create winners and losers among pharma companies in the race to build the most effective supply chain.
The most successful companies are those with flexible R&D allocation, according to BCG’s Michael Ringel in an article published in Nature Reviews Drug Discovery. These companies actively pursue and invest in the right new scientific opportunities, balance quantitative and qualitative information on scientific feasibility and market need, employ incentives that drive “truth seeking,” and introduce variability into the cost base to enable flexibility in year-to-year investment levels.
PL
